Rifaximin and crohn's disease: A new solution to an old problem?

Digestive Diseases and Sciences

Volumn 55, Issue 4, 2010, Pages 877-879

  Day, A S ^a,b   Gearry, R B ^a,b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b CHRISTCHURCH HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; CORTICOSTEROID; IMMUNOMODULATING AGENT; METRONIDAZOLE; PLACEBO; PROBIOTIC AGENT; RIFAXIMIN; ANTIINFECTIVE AGENT; GASTROINTESTINAL AGENT; RIFAMYCIN;

ABDOMINAL PAIN; CLINICAL TRIAL; COLITIS; CROHN DISEASE; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG TOLERABILITY; EDITORIAL; FATIGUE; HUMAN; INTESTINE FLORA; MATERNAL NUTRITION; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; RECURRENT DISEASE; REMISSION; TRAVELLER DIARRHEA; TREATMENT DURATION; ADULT; CHILD; DOSE RESPONSE; LONG TERM CARE; MICROBIOLOGY; NOTE; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; ANTI-INFECTIVE AGENTS; CHILD; CROHN DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; GASTROINTESTINAL AGENTS; HUMANS; LONG-TERM CARE; RETROSPECTIVE STUDIES; RIFAMYCINS; TREATMENT OUTCOME;

EID: 77950352413     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-010-1140-6     Document Type: Editorial

References (17)

1. Shafran I, Burgunder P. Adjunctive antibiotic therapy with rifaximin may help reduce Crohn's disease activity. Dig Dis Sci. 2010. doi: 10.1007/s10620-009-1111-y
2. AM Griffiths 2004 Specificities of inflammatory bowel disease in childhood Best Pract Res Clin Gastroenterol 18 509 523 10.1016/j.bpg.2004.01.002 15157824 (Pubitemid 38667463)
3. RB Sartor 1997 Enteric microflora in IBD: pathogens or commensals? Inflamm Bowel Dis 3 230 235 10.1002/ibd.3780030309
4. C Fiocchi 1998 Inflammatory bowel disease: etiology and pathogenesis Gastroenterology 115 182 205 10.1016/S0016-5085(98)70381-6 1:STN:280: DyaK1czitlGjtg%3D%3D 9649475 (Pubitemid 28307304)
5. SM Man L Zhang AS Day S Leach HM Mitchell 2008 Detection of enterohepatic and gastric Helicobacter species in fecal specimens of children with Crohn's Disease Helicobacter 13 234 238 10.1111/j.1523-5378.2008.00607.x 1:CAS:528:DC%2BD1cXpslKns7w%3D 18665930
6. L Zhang SM Man AS Day, et al. 2009 Non-jejuni Campylobacter species are associated with Crohn's disease in children J Clin Micro 47 453 455 10.1128/JCM.01949-08
7. A Swidsinski V Loening-Baucke M Vaneechoutte Y Doerffel 2008 Active Crohn's disease and ulcerative colitis can be specifically diagnosed and monitored based on the biostructure of the fecal flora Inflamm Bowel Dis 14 147 161 10.1002/ibd.20330 18050295 (Pubitemid 351288036)
8. HC Rath M Schultz R Freitag, et al. 2001 Different subsets of enteric bacteria induce and perpetuate experimental colitis in rats and mice Infect Immun 69 2277 2285 10.1128/IAI.69.4.2277-2285.2001 1:CAS:528: DC%2BD3MXisVSlsrw%3D 11254584 (Pubitemid 32241818)
9. KL Madsen JS Doyle MM Tavernini, et al. 2000 Antibiotic therapy attenuates colitis in interleukin 10 gene-deficient mice Gastroenterology 118 1094 1105 10.1016/S0016-5085(00)70362-3 1:CAS:528:DC%2BD3cXktlaiurk%3D 10833484
10. KL Madsen JS Doyle LD Jewell MM Tavernini RN Fedorak 1999 Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice Gastroenterology 116 1107 1114 10.1016/S0016-5085(99)70013-2 1:STN:280:DyaK1M3jvVyrtg%3D%3D 10220502 (Pubitemid 29203020)
11. GR D'Haens K Geboes M Peeters, et al. 1998 Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum Gastroenterology 114 262 267 10.1016/S0016-5085(98)70476-7 9453485 (Pubitemid 28093532)
12. ST Leach HM Mitchell WR Eng L Zhang AS Day 2008 Sustained modulation of intestinal microflora by exclusive enteral nutrition used to treat children with Crohn's disease Aliment Pharmacol Ther 28 724 733 10.1111/j.1365-2036.2008. 03796.x 1:CAS:528:DC%2BD1cXhtF2hs7%2FL 19145728
13. C Prantera ML Scribano 2009 Antibiotics and probiotics in inflammatory bowel disease: why, when, and how Curr Opin Gastroenterol 25 329 333 10.1097/MOG.0b013e32832b20bf 1:CAS:528:DC%2BD1MXnsVegsrc%3D 19444096
14. I Shafran LK Johnson 2005 An open-label evaluation of rifaximin in the treatment of active Crohn's disease Curr Med Res Opin 1 1165 1169 10.1185/030079905X53252 (Pubitemid 41140719)
15. C Prantera H Lochs M Campieri, et al. 2006 Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin Aliment Pharmacol Ther 23 1117 1125 10.1111/j.1365-2036.2006.02879.x 1:CAS:528:DC%2BD28Xlt1aktb8%3D 16611272 (Pubitemid 43779351)
16. P Muniyappa R Gulati F Mohr V Hupertz 2009 Use and safety of rifaximin in children with inflammatory bowel disease Pediatr Gastroenterol Nutr 49 400 404 10.1097/MPG.0b013e3181a0d269 1:CAS:528:DC%2BD1MXhtFOhtr3M
17. DB Doman HJ Goldberg MI Golding 2008 "Ecologic niche" therapy for Crohn's disease with adjunctive rifaximin antibiotic treatment followed by Flora-Q probiotic maintenance therapy Am J Gastroenterol 103 251 252 18184139